A Study to Evaluate the Effects of Cenicriviroc Mesylate on Arterial Inflammation in People Living With HIV

NCT05630885 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

110

Enrollment

NIH

Sponsor class

Conditions

HIV-1-infection
Elevated Cardiovascular Risk

Interventions

DRUG: CVC 150 mg
DRUG: CVC 300 mg
OTHER: Placebo for CVC 150 mg
OTHER: Placebo for CVC 300 mg

Sponsor

National Institute of Allergy and Infectious Diseases (NIAID)

Collaborators

[object Object]